Johnson & Johnson $JNJ Shares Sold by Associated Banc Corp

Associated Banc Corp trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 145,603 shares of the company’s stock after selling 3,508 shares during the period. Associated Banc Corp’s holdings in Johnson & Johnson were worth $22,241,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Nuveen LLC purchased a new stake in Johnson & Johnson in the first quarter valued at $1,369,188,000. Laurel Wealth Advisors LLC boosted its stake in shares of Johnson & Johnson by 15,040.6% in the second quarter. Laurel Wealth Advisors LLC now owns 7,420,699 shares of the company’s stock worth $1,133,512,000 after buying an additional 7,371,687 shares during the last quarter. Vanguard Group Inc. grew its holdings in Johnson & Johnson by 1.3% during the second quarter. Vanguard Group Inc. now owns 237,047,859 shares of the company’s stock worth $36,209,060,000 after acquiring an additional 3,085,180 shares during the period. Assenagon Asset Management S.A. raised its position in Johnson & Johnson by 159.6% during the second quarter. Assenagon Asset Management S.A. now owns 4,159,260 shares of the company’s stock valued at $635,327,000 after acquiring an additional 2,557,388 shares in the last quarter. Finally, Kingstone Capital Partners Texas LLC acquired a new position in Johnson & Johnson in the second quarter valued at approximately $401,420,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. The Goldman Sachs Group raised their price objective on shares of Johnson & Johnson from $186.00 to $212.00 and gave the stock a “buy” rating in a research note on Thursday, October 9th. Scotiabank started coverage on shares of Johnson & Johnson in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $230.00 price target on the stock. Argus set a $210.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 15th. Royal Bank Of Canada reissued an “outperform” rating and set a $209.00 target price on shares of Johnson & Johnson in a research note on Friday, October 10th. Finally, Stifel Nicolaus lifted their price target on Johnson & Johnson from $165.00 to $190.00 and gave the company a “hold” rating in a research note on Wednesday, October 15th. Four research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $201.05.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $206.07 on Tuesday. The company has a fifty day simple moving average of $188.83 and a 200-day simple moving average of $172.13. The firm has a market capitalization of $496.48 billion, a price-to-earnings ratio of 19.89, a PEG ratio of 2.19 and a beta of 0.38. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $206.94.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The firm had revenue of $24.02 billion for the quarter. On average, equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.5%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 50.19%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.